MY151439A - Medium-chain length fatty acids and glycerides as nephroprotection agents - Google Patents
Medium-chain length fatty acids and glycerides as nephroprotection agentsInfo
- Publication number
- MY151439A MY151439A MYPI2010001861A MYPI20101861A MY151439A MY 151439 A MY151439 A MY 151439A MY PI2010001861 A MYPI2010001861 A MY PI2010001861A MY PI20101861 A MYPI20101861 A MY PI20101861A MY 151439 A MY151439 A MY 151439A
- Authority
- MY
- Malaysia
- Prior art keywords
- nephroprotection
- agents
- medium
- fatty acids
- chain length
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 125000005456 glyceride group Chemical group 0.000 title 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000005639 Lauric acid Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 230000001434 glomerular Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000013059 nephrectomy Methods 0.000 abstract 1
- 229960002446 octanoic acid Drugs 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98509407P | 2007-11-02 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY151439A true MY151439A (en) | 2014-05-30 |
Family
ID=40590499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010001861A MY151439A (en) | 2007-11-02 | 2008-11-03 | Medium-chain length fatty acids and glycerides as nephroprotection agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9532962B2 (enExample) |
| EP (1) | EP2299998B1 (enExample) |
| JP (1) | JP5575655B2 (enExample) |
| KR (1) | KR101601987B1 (enExample) |
| CN (1) | CN101878028A (enExample) |
| AU (1) | AU2008318196B2 (enExample) |
| BR (1) | BRPI0818310A8 (enExample) |
| CA (1) | CA2704286C (enExample) |
| DK (1) | DK2299998T3 (enExample) |
| ES (1) | ES2664594T3 (enExample) |
| IL (1) | IL205362A (enExample) |
| MX (1) | MX338513B (enExample) |
| MY (1) | MY151439A (enExample) |
| NO (1) | NO2299998T3 (enExample) |
| NZ (1) | NZ584981A (enExample) |
| PT (1) | PT2299998T (enExample) |
| RU (1) | RU2519215C2 (enExample) |
| WO (1) | WO2009055933A1 (enExample) |
| ZA (1) | ZA201003030B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2427416B1 (en) | 2009-05-04 | 2016-03-09 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical uses thereof |
| JP5706142B2 (ja) * | 2010-04-28 | 2015-04-22 | 株式会社ファンケル | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤 |
| CN105997967B (zh) | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| US9393224B2 (en) | 2011-08-26 | 2016-07-19 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
| KR20130023583A (ko) * | 2011-08-29 | 2013-03-08 | 아주대학교산학협력단 | 파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물 |
| US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
| WO2017074266A1 (en) * | 2015-10-30 | 2017-05-04 | National University Of Singapore | Androgen biosynthesis inhibitor |
| CN105559071A (zh) * | 2016-01-12 | 2016-05-11 | 刘保惠 | 一种适用于肾病的特殊医学用途配方食品及其制备方法 |
| JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
| NZ749389A (en) | 2016-06-08 | 2022-12-23 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| WO2018115953A1 (en) * | 2016-12-21 | 2018-06-28 | Prometic Pharma Smt Limited | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition |
| JP7055429B2 (ja) * | 2017-10-27 | 2022-04-18 | 学校法人北里研究所 | 慢性腎臓病の予防又は治療剤 |
| US20190240180A1 (en) * | 2018-02-08 | 2019-08-08 | Nestec Sa | Mct-based nutrition blend for providing health benefits in companion animals |
| MA53188A1 (fr) | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
| CN109602012A (zh) * | 2018-12-11 | 2019-04-12 | 李卫平 | 一种功能性低蛋白能量米及其制备方法 |
| CN111184728B (zh) * | 2020-02-20 | 2023-04-04 | 上海市儿童医院 | 海藻糖在肾病综合征中的应用 |
| EP4539686A1 (en) * | 2022-06-15 | 2025-04-23 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| JP2024176004A (ja) * | 2023-06-07 | 2024-12-19 | リファインホールディングス株式会社 | 小胞体ストレス抑制剤、慢性腎臓病疾患予防改善剤および食品 |
| CN118592613B (zh) * | 2024-08-05 | 2025-01-07 | 杭州康源食品科技有限公司 | 中链脂肪酸混合结构脂在改善膳食诱导的糖脂代谢紊乱中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602040A (en) | 1983-04-18 | 1986-07-22 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
| US4737384A (en) * | 1985-11-01 | 1988-04-12 | Allied Corporation | Deposition of thin films using supercritical fluids |
| EP0583480A4 (en) | 1992-02-07 | 1994-03-18 | Tsumura & Co | Side-effect alleviant. |
| US6689700B1 (en) * | 1999-11-02 | 2004-02-10 | University Of Massachusetts | Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates |
| JP5259905B2 (ja) | 2000-06-20 | 2013-08-07 | エヌ・ブイ・ニュートリション・サイエンシス | 抗菌剤として適用可能な中鎖脂肪酸 |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| DK1900364T3 (da) * | 2001-04-18 | 2014-01-13 | Prometic Biosciences Inc | Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer |
| CN1827766B (zh) | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
| RU2213570C2 (ru) * | 2001-08-22 | 2003-10-10 | Санкт-Петербургская Государственная Химико-Фармацевтическая Академия | ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ |
| US7030168B2 (en) * | 2001-12-31 | 2006-04-18 | Advanced Technology Materials, Inc. | Supercritical fluid-assisted deposition of materials on semiconductor substrates |
| US20040052836A1 (en) * | 2002-09-13 | 2004-03-18 | Li Luk Chiu | Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life |
| BRPI0407276A (pt) | 2003-02-07 | 2006-01-31 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese |
| PL1648851T3 (pl) | 2003-07-25 | 2007-09-28 | Prometic Biosciences Inc | Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami |
| EP1940379A4 (en) | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
-
2008
- 2008-11-03 US US12/740,700 patent/US9532962B2/en not_active Expired - Fee Related
- 2008-11-03 ES ES08845122.4T patent/ES2664594T3/es active Active
- 2008-11-03 KR KR1020107012064A patent/KR101601987B1/ko not_active Expired - Fee Related
- 2008-11-03 CN CN200880113724XA patent/CN101878028A/zh active Pending
- 2008-11-03 PT PT88451224T patent/PT2299998T/pt unknown
- 2008-11-03 BR BRPI0818310A patent/BRPI0818310A8/pt not_active IP Right Cessation
- 2008-11-03 CA CA2704286A patent/CA2704286C/en not_active Expired - Fee Related
- 2008-11-03 JP JP2010532389A patent/JP5575655B2/ja not_active Expired - Fee Related
- 2008-11-03 NO NO08845122A patent/NO2299998T3/no unknown
- 2008-11-03 EP EP08845122.4A patent/EP2299998B1/en not_active Not-in-force
- 2008-11-03 NZ NZ584981A patent/NZ584981A/en not_active IP Right Cessation
- 2008-11-03 MY MYPI2010001861A patent/MY151439A/en unknown
- 2008-11-03 MX MX2010004856A patent/MX338513B/es active IP Right Grant
- 2008-11-03 RU RU2010122302/15A patent/RU2519215C2/ru active
- 2008-11-03 DK DK08845122.4T patent/DK2299998T3/en active
- 2008-11-03 WO PCT/CA2008/001930 patent/WO2009055933A1/en not_active Ceased
- 2008-11-03 AU AU2008318196A patent/AU2008318196B2/en not_active Ceased
-
2010
- 2010-04-26 IL IL205362A patent/IL205362A/en active IP Right Grant
- 2010-04-30 ZA ZA2010/03030A patent/ZA201003030B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009055933A1 (en) | 2009-05-07 |
| CA2704286A1 (en) | 2009-05-07 |
| US20100286269A1 (en) | 2010-11-11 |
| JP5575655B2 (ja) | 2014-08-20 |
| ES2664594T3 (es) | 2018-04-20 |
| BRPI0818310A2 (pt) | 2017-10-10 |
| EP2299998B1 (en) | 2018-01-03 |
| EP2299998A1 (en) | 2011-03-30 |
| JP2011502174A (ja) | 2011-01-20 |
| PT2299998T (pt) | 2018-04-02 |
| NZ584981A (en) | 2012-05-25 |
| IL205362A0 (en) | 2010-12-30 |
| KR101601987B1 (ko) | 2016-03-09 |
| ZA201003030B (en) | 2011-02-23 |
| DK2299998T3 (en) | 2018-03-26 |
| US9532962B2 (en) | 2017-01-03 |
| AU2008318196A1 (en) | 2009-05-07 |
| EP2299998A4 (en) | 2011-03-30 |
| BRPI0818310A8 (pt) | 2017-12-26 |
| MX2010004856A (es) | 2010-06-30 |
| AU2008318196B2 (en) | 2014-04-10 |
| CN101878028A (zh) | 2010-11-03 |
| RU2010122302A (ru) | 2011-12-10 |
| MX338513B (es) | 2016-04-20 |
| KR20100106958A (ko) | 2010-10-04 |
| RU2519215C2 (ru) | 2014-06-10 |
| CA2704286C (en) | 2016-08-23 |
| IL205362A (en) | 2015-01-29 |
| NO2299998T3 (enExample) | 2018-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010004856A (es) | Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. | |
| WO2007073486A3 (en) | Methods and compositions for delivering active agents with enhanced pharmacological properties | |
| EP2671584A3 (en) | Compositions and methods for treating disorders associated with salt or fluid retention | |
| NZ591057A (en) | Complement antagonists and uses thereof | |
| WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
| WO2012019188A3 (en) | Methods and compositions for the inhibition of fructokinase | |
| CL2012002317A1 (es) | Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras. | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX381737B (es) | Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. | |
| WO2009063222A3 (en) | Solid compositions | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| EP2211913A4 (en) | SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS | |
| EP2638903A4 (en) | SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR | |
| JP2010222367A5 (enExample) | ||
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
| TN2012000059A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
| MX368109B (es) | Terapia de combinacion con epoxicetonas peptidicas. | |
| WO2012053013A3 (en) | Pharmaceutical compositions of anti-acne agents | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| MX385881B (es) | Forma de dosificacion de alivio prolongado | |
| EP2167071A4 (en) | BACLOFEN SOLUTION FOR LOW VOLUME THERAPEUTIC DELIVERY |